

## **Precisis AG – EASEE®**

### **European Multicenter Study gets green light**

**Heidelberg, Oct 18<sup>th</sup> 2018. EASEE®**, the innovative brain stimulation system developed by Precisis AG, has successfully completed the preclinical trial phase. For the first time, patients suffering from focal epilepsy who do not respond to drug treatment will now be given the opportunity to positively affect the course of their illness using brain stimulation.

After years of preparation, the moment has finally come for the researchers at Precisis AG: the competent authorities and commissions decided that patients should be able to benefit from this entirely new form of treatment, giving the go-ahead for the innovative brain-stimulation system EASEE® to be implanted and evaluated in humans for the first time. The new system will be made available to patients suffering from drug-resistant focal epilepsy in clinical trials at specialist centres across Europe.

### **Electrical impulses stabilise the diseased brain area**

First, a thin mat incorporating five small platelet electrodes is implanted under the scalp above the area of the brain from where the patient's seizures originate. This is a simple, minimally invasive procedure without the necessity to open up the skull. Powered by an impulse generator positioned on the pectoral muscle, EASEE® sends electrical signals to the brain. The purpose of superficial brain stimulation is to stabilise the diseased over-reactive areas of the brain using individually adjustable electrical impulses.

### **Small intervention with great potential**

In cases where drug treatment fails, the EASEE® brain stimulation system offers affected patients a new opportunity to positively influence the course of their illness. Professor Andreas Schulze-Bonhage, Medical Director of the Epilepsy Centre at the University of Freiburg Medical Centre and head of the study is confident that EASEE® offers extended opportunities to broaden the treatment options for patients suffering from inoperable focal epilepsy. "Time and again we see patients whom we are unable to help sufficiently using drug treatments alone but who also cannot be treated by brain surgery. These are exactly the people for whom EASEE® was developed," says Schulze-Bonhage.

### **EASEE® – Hope for patients with cognitive impairments**

The aim of the study is to assess any reductions in both the frequency and the severity of seizures as well as the safety of the system. In addition, all participants hope that EASEE® will also have a supportive effect in patients suffering from concomitant cognitive impairments.

### **About Precisis AG**

Precisis AG was founded in 2004. The company, headquartered in Heidelberg, specialises in the development of innovative medical devices.

Precisis AG stands for outstanding success in the field of device-controlled brain therapies. Committed to achieving progress, we provide innovative solutions in the fields of neurosurgery, radiation therapy and stereotaxy by developing customised, high-quality medical technology for use in high-precision interventions in humans – making life easier for doctors and their patients. Our software and hardware are used in the treatment of Parkinson's disease and in

cancer treatment. In addition, the progress made in brain stimulation has given us new treatment options for diseases such as epilepsy, Alzheimer's, dementia or severe clinical depression. Our staff has a deep understanding of ethics and the responsible use of complex technical opportunities. Collaboration with strong partners paves the way for reliable, customised and well-tolerated solutions for people with functional brain disease.

For further information on the activities, progress and milestones of Precisis AG, visit our website: [www.precisis.de/en](http://www.precisis.de/en)

**Contact and further information:**

Precisis AG  
Hauptstrasse 73  
69117 Heidelberg  
Germany  
+49 6221 6559300  
info@precisis.de  
**www.precisis.de**

**Press service:**

WEFRA PR  
Public Relations Agency  
Isabell Grafe  
Telephone: +49 6969 500 8 57  
Email: ig@wefra.de